FRM
ALT icon

Fox Run Management’s Altimmune ALT Stock Holding History

Fox Run Management’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,603
Closed -$110K – 878
2025
Q4 		$110K Buy
+30,603
New +$133K 0.02% 852
2025
Q2 		– Sell
-38,200
Closed -$191K – 837
2025
Q1 		$191K Buy
38,200
+25,295
+196% +$160K 0.03% 806
2024
Q4 		$93K Buy
+12,905
New +$98.6K 0.02% 811
2023
Q2 		– Sell
-30,435
Closed -$128K – 664
2023
Q1 		$128K Buy
+30,435
New +$362K 0.04% 586
2022
Q4 		– Sell
-12,823
Closed -$164K – 597
2022
Q3 		$164K Buy
+12,823
New +$189K 0.06% 509
2021
Q4 		– Sell
-11,165
Closed -$126K – 459
2021
Q3 		$126K Buy
+11,165
New +$136K 0.08% 411

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Fox Run Management's ALT Position: Q1 2026 in Review

Fox Run Management sold out of Altimmune (ALT) in Q1 2026, closing a stake of 30,603 shares — an estimated $110K sold.

Fox Run Management first reported a position in ALT in Q3 2021 and held it in 6 quarters. The position peaked at $191K in Q1 2025. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

  • Fox Run Management reported no remaining Altimmune position as of Q1 2026 after selling out during the quarter.
  • Fox Run Management sold 30,603 Altimmune shares in Q1 2026, an estimated $110K.
  • Fox Run Management first reported a position in Altimmune in Q3 2021 and held it in 6 quarters.
  • Fox Run Management's Altimmune position peaked at $191K in Q1 2025.
  • 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.